| Literature DB >> 27829934 |
Mateusz T Zamkowski1, Wojciech Makarewicz2, Jerzy Ropel1, Maciej Bobowicz3, Michał Kąkol4, Maciej Śmietański5.
Abstract
More than 1 million inguinal hernia repairs are performed in Europe and the US annually. Although antibiotic prophylaxis is not required in clean, elective procedures, the routine use of implants (90% of inguinal hernia repairs are performed with mesh) makes the topic controversial. The European Hernia Society does not recommend routine antibiotic prophylaxis for elective inguinal hernia repairs. However, the latest randomized controlled trial, published by Mazaki et al., indicates that the use of prophylaxis is effective for the prevention of surgical site infection. Unnecessary prophylaxis contributes to the development of bacterial resistance and significantly increases healthcare costs. This review documents clinical trials on inguinal hernia repairs with mesh and summarizes the current knowledge. It also tries to solve certain problems, namely: what constitutes a real risk factor, late-onset infection, and how the "surgical environment" impacts on the need to use antibiotic prophylaxis.Entities:
Keywords: antibiotic prophylaxis; antimicrobial prophylaxis; hernia; inguinal hernia repair; mesh repair; surgical site infection
Year: 2016 PMID: 27829934 PMCID: PMC5095278 DOI: 10.5114/wiitm.2016.62800
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Types of surgical wounds and the risk of infection
| Types of surgical wounds and the risk of infection | Risk of infection (%) | |
|---|---|---|
| Clean | Elective procedure, primarily closed wound without trauma and with no evidence of infection or inflammation in the surgical site. Without compromising the integrity of the gastrointestinal tract, urogenital tract, respiratory tract, oral cavity and pharynx – providing aseptic technique has been used | < 2 |
| Clean-contaminated | Procedures in which the urinary, respiratory or gastrointestinal tracts are entered under controlled conditions, without evident contamination with their contents. Procedures involving the biliary tract with no evidence of infection; procedures involving access through the oropharyngeal mucosa; clean emergency procedures; repeat surgery within 7 days of a clean procedure. Blunt trauma | < 10 |
| Contaminated | Open post-traumatic wound, procedure with a violation of the aseptic technique; inflammation other than surgical site infection; penetrating trauma within less than 4 h of the procedure; chronic wound eligible for treatment with a skin graft | 20 |
| Dirty | Penetrating trauma within more than 4 h of the procedure; procedures involving devitalised tissues; evidence of infection at the surgical site. Preoperative perforation of the gastrointestinal, biliary or respiratory tracts | 40 |
Randomized controlled trials
| First author, year | Country | Control group | Sample size | Infections | Sample size | Sample size | Infections | ||
|---|---|---|---|---|---|---|---|---|---|
| % | % | ||||||||
| Morales, 2000 | Spain | Placebo | 287 | 6 | 2.09 | Cefazolin 2 g. | 237 | 4 | 1.7 |
| Yerdel, 2001 | Turkey | Placebo | 133 | 12 | 9.0 | Ampicillin + sulbactam 1.5 g. i.v. | 136 | 1 | 0.7 |
| Aufenacker, 2004 | Netherlands | Placebo | 505 | 9 | 1.8 | Cefazolin 1 g. | 503 | 8 | 1.6 |
| Celdran, 2004 | Spain | Placebo | 49 | 4 | 8 | Cefazolin 1 g. | 50 | 0 | 0 |
| Oteiza, 2004 | Spain | No treatment | 123 | 0 | 0 | Amoxicillin + clavulanic acid 2 g | 124 | 1 | |
| Perez, 2005 | Philippines | Placebo | 180 | 7 | 3.9 | Cefazolin 1 g. | 180 | 4 | 2.2 |
| Tzoravas, 2007 | Greece | Placebo | 193 | 9 | 4.6 | Amoxicillin + clavulanic acid 1.2 g. | 193 | 5 | 2.6 |
| Jain, 2008 | India | Placebo | 60 | 1 | 1.7 | Amoxicillin + clavulanic acid 1.2 g. | 60 | 1 | 1.7 |
| Shankar, 2010 | India | Placebo | 162 | 17 | 10.5 | Cefazolin 1 g . | 172 | 12 | 7 |
| Ergul, 2011 | Turkey | Placebo | 100 | 7 | 7 | Cefazolin 1 g . | 100 | 5 | 5 |
| Othman, 2011 | Egypt | Placebo | 48 | 6 | 2.88 | Amoxicillin + clavulanic acid 1.2 g. | 50 | 4 | 2 |
| Mazaki, 2013 | Japan | Placebo | 100 | 13 | 13 | Cefazolin 1 g. | 100 | 2 | 2 |
| 1940 | 91 | 4.7 | 1905 | 47 | 2.5 | ||||